# E-B-FAHF-2, Multi OIT and Xolair for Food Allergy

> **NCT06103656** · PHASE2 · COMPLETED · sponsor: **New York Medical College** · enrollment: 33 (actual)

## Conditions studied

- Food Allergy

## Interventions

- **DRUG:** Drug: Chinese Herbal Medication
- **DRUG:** Drug: Placebo
- **DRUG:** Drug: Omalizumab

## Key facts

- **NCT ID:** NCT06103656
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-20
- **Primary completion:** 2020-07-02
- **Final completion:** 2021-02-22
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06103656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06103656, "E-B-FAHF-2, Multi OIT and Xolair for Food Allergy". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT06103656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*